In Sepsis, Having the Right Drug Still May Not Be Enough
In conjunction with the initial sales numbers for its sepsis drug, Xigris, manufacturer Eli Lilly cautioned that "the selection of patients with severe sepsis as indicated on the label has been complex for physicians initially." To address the knowledge gap, the National Institutes of Health has awarded a $6 million grant for a study of risk factors for sepsis, the first study of its kind and the biggest single R1 grant ever funded through NIH's National Institute of General Medical Sciences. The Xigris pivotal trial was the only one of 31 Phase III trials of sepsis drugs that didn't fail. "It's not just understanding how the drug works, it's believing in it," says the principal investigator for the NIH study, which should help move the process forward.
Eli Lilly & Co. 's update on
early sales of its sepsis drug, Xigris (drotrecogin alfa, or
activated protein C) serves as a reminder that even with a new drug
finally in hand to treat this often rapidly fatal disease, the
inability to diagnose sepsis early remains a significant clinical
challenge.
Since Xigris's launch in late November, sales have reached $35 million—$14 million of it coming in the first two months...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
As president of US Hematology at J&J, June Lanoue's leadership approach focuses on improving patient outcomes and organizational development. Her career path demonstrates the role of curiosity and adaptability in health care advancement.
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
